1. А. В. Отт, Г. А.Чумакова, Н. Г. Веселовская. Эпикардиальное ожирение как один из основных критериев метаболического тучного фенотипа ожирения. 1,2,DOI: 10.20333/2500136-2017-4-44-53. [A. V. Ott, G. A.Chumakova, N. G. Veselovskaya.Epicardial obesity as main criteria of metabolic obese phenotype of obesity. 1,2,DOI: 10.20333/2500136-2017-4-44-53.]
2. Бояринова МА, Ротарь ОП, Конради АО. Адипокины и кардиометаболический синдром.Артериальная гипертензия. 2014;20(5):422-432. [Boyarinova MA, Rotar’ OP, Konradi AO. Adipokines and cardiomethabolic syndrome. Arterial hypertension. 2014;20(5):422-432.]
3. Н.В.Блинова, Ю.В.Жернакова и др. Эпикардиальный жир: новый маркер кардиометаболического риска – новая терапевтическая цель у пациентов с ожирением. DOI: 10.26442/2075082X.2018.4.1 80111. Системные гипертензии | 2018 | том15|№4 66-69. [N.V.Blinova, Yu.V.Zhernakovaetal.Epicardial fat: new marker of cardiovascular disease-new management goal for patients with obesity. Systemic hypertension | 2018 |№4 66-69].
4. О.М. Драпкина*, О.Н. Корнеева, Ю.С. Драпкина. Рациональная фармакотерапия в кардиологии 2013;9(3):287-291. [O.M. Drapkina*,O.N. Korneeva, Yu.S. Drapkina. Rational Pharmacotherapy in Cardiology 2013;9(3):287-291].
5. Drapkina O. M. Application of essential phospholipids in the treatment of NASH mixed origin. Consilium medicum 2009; (2): 3–5. Russian (Драпкина О. М.Применение эссенциальных фосфолипидов в комплексной терапии стеатогепатита смешанного генеза. Consilium medicum 2009; (2): 3–5).
6. Eckel N, Li Y, Kuxhaus O et al. Transition from metabolic healthy to unhealthy phenotypes and association with cardiovascular disease risk across BMI categories in 90 257 women (the Nurses’ Health Study): 30 year follow-up from a prospective cohort study. Lancet Diabetes Endocrinol 2018.DOI:10.1016/S2213-8587(18)30137-2
7. Fain J.N., Sacks H.S., Bahouth S.W., Tichansky D.S., Madan A.K., Cheema P.S. Human epicardial adipokine messenger RNAs: comparisons of their expression in substernal, subcutaneous, and omental fat. Metabolism: Сlinical and Еxperimental. 2010; 59 (1): 379–386.
8. Hirata Y, Tabata M, Kurobe H et al. Coronary atherosclerosis is associated with macrophage polarization in epicardial adipose tissue. J Am Coll Cardiol 2011; 58: 248–55. DOI: 10.1016/j.jacc.2011.01.048
9. Iacobellis G, Assael F, Ribaudo M, et al. Epicardial fat from echocardio graphy: a new method for visceral adipose tissue predic tion. Obes Res, 2003,11:304–10.
10. Iacobellis G., Bianco A.C. Epicardial adipose tissue:emerging physiological, pathophysiological and clinical features. Trends Endocrinol. Metab. 2011;22 (11): 450– 457. DOI: 10.1016/j.tem.2011.07.003.
11. Iacobellis G, Corradi D, Sharma AM. Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart. Nature clinical practice. Cardiovascular medicine. 2005;2:536-43. DOI:10.1038/ncpcardio0319.
12. Iacobellis G., Ribaudo M.C., Assael F., Vecci E., Tiber- ti C., Zappaterreno A., Di Mario U.,Leonetti F. Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk. J. Clin. Endocrinol. Metab.2003; 88: 5163–5168. DOI: 10.1210/jc.2003-030698/
13. Iacobellis G, Ribaudo MC, Zappaterreno A et al. Relation between epicardial adipose tissue and left ventricular mass. Am J Cardiol 2004; 94: 1084–7.DOI: 10.1016/j.amjcard.2004.06.075 Iacobellis G, Singh N, Wharton S, Sharma AM.Substantial changes in epicardial fat thickness after weight loss in severely obese subjects. Obesity (Silver Spring) 2008; 16 (7): 1693–7. DOI:10.1038/ oby.2008.251
14. Iozzo P. Metabolic toxicity of the heart: insights from molecular imaging. Nutr. Metab. Cardiovasc.Dis. 2010; 20 (3): 147–156. DOI: 10.1016/j.numecd.2009.08.011.
15. Lopaschuk G.D. Metabolic abnormalities in the diabetic heart. Heart Fail. Rev. 2002; 7 (2): 149–159.
16. Mazurek T, Kiliszek M, Kobylecka M et al. Relation of proinfl ammatory activity of epicardial adipose tissue to the occurrence of atrial fi brillation. Am J Cardiol 2014; 113: 1505–8. DOI:10.1016/j. amjcard.2014.02.005
17. Mazurek T, Zhang LF, Zalewski A et al. Human epicardial adipose tissue is a source of infl ammatory markers. Circulation 2003; 108: 2460–6. DOI:10.1161/01.CIR.0000099542.57313.C5
18. Montani JP , Carroll JF , Dwyer TM. Ectopic fat storage in heart, blood vessels and kidneys in the pathogenesis of cardiovascular diseases. Int J Obes Relat Metab Disord 2004; 28 (4): 58–65.
19. Moore KL, Persaud TN. The developing human.Clinically oriented embryology. 7th ed. Philadelphia,PA: Saunders; 2003.
20. Nelson MR, Mookadam F , Thota V . Epicardial Fat: An Additional Measurement for Subclinical Atherosclerosis and Cardiovascular Risk Stratifi cation. J Am Soc Echocardiogr 2011; 24 (3):339–45.
21. Sacks HS, Fain JN, Cheema P et al. Infl ammatory genes in epicardial fat contiguous with coronary atherosclerosis in the metabolic syndrome and type 2 diabetes: changes associated with pioglitazone. Diabetes Care 2011; 34: 730–3. DOI: 10.2337/dc10-2083
22. Sacks H.S., Fain J.N. Human epicardialadipose tissue: a review. Am. Heart J. 2007; 153: 907–917.DOI: 10.1016/j. ahj.2007.03.019. Sun K, Kusminski C, Scherer P . Adipose tissue remodeling and obesity. J Clin Invest 2011; 121 (6): 2094–101. DOI: 10.1172/JCI45887; Hajer G,
23. Haeften T, Visseren F. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 2008; 29: 2959–71. DOI:10.1093/eurheartj/ehn387.